RxDoctor Payments Data

Benjeil Edghill, MD

Ophthalmology · Staten Island, NYNPI 1659392520

Payments from drug & device makers

$22,611in general payments, 2019–2025

Across 73 payments — averaging $309.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$17K
  • Ivantis, Inc$2K
  • AbbVie$725
  • Sun Pharmaceutical Industries Inc.$583
  • Aerie Pharmaceuticals, Inc.$308
  • Genentech USA, Inc.$146
  • plus $887 from 10 others

What the payments were for

  • Consulting fees$2,0009%
  • Speaking & faculty fees$16,03871%
  • Food & beverage$4,55320%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,611 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$186,173
Medicare patients
317
Services billed
1,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate113$59,877
LumiganBimatoprost68$42,900
CombiganBrimonidine Tartrate/Timolol32$27,012
Bromfenac Sodium78$18,033
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat626$16,630
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol48$16,082
RocklatanNetarsudil Mesylat/Latanoprost31$15,370
Latanoprost1,098$13,265
RestasisCyclosporine15$10,663
ProlensaBromfenac Sodium27$10,008
Brimonidine Tartrate302$7,229
Azelastine Hcl283$6,697
Ketorolac Tromethamine381$6,638
Flurbiprofen Sodium125$6,598
SimbrinzaBrinzolamide/Brimonidine Tart14$5,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis$725$80,575115 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$308$75,246144 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$100$10,00827 claims
AlconSimbrinza$142$5,26214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →